Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

First decisions about add-on reimbursement by CNEDiMTS at French National Authority for Health (HAS) from the meeting in April 2017

17 May 2017

At the meeting of 18th of April National Commission for Evaluation of Medical Devices and Health Technologies made decisions about add-on reimbursement of 17 medical devices. Ten decisions have been released to date for orthopedic, osteointegrated processing, cardiac and intravascular devices:

Decisions are pending about the following technologies:

  • ULTIMASTER, coronary endoprosthesis with sirolimus (renewal of condition for registration)
  • MAGNEZIX CS, bioresorbable screw for osteosynthesis (application for registration)
  • ESSURE, Intrafallopian implant - device for hysteroscopic tubal sterilization (5260 and DM_EVAL-143) (renewal of registration)
  • PENUMBRA 3D, thrombus reuptake system (retriever) (5251), PENUMBRA PACKAGE SYSTEM, Thrombus aspiration kit (ACE60 and ACE68) (5235) (application for registration)
  • MELODY with percutaneous implant system ASSEMBLY, percutaneous ultrasonic valve with implantation system (5264) (renewal of registration)
  • MELODY with percutaneous implant system ASSEMBLE II, Percutaneous pulmonary valve with implantation system (5223) (application for registration)
  • RESORB X (range) and SONICPINS RX, Resorbable plates and rivets for craniofacial osteosynthesis (5255) (application for registration)

Publications of opinions for these technologies are awaiting.

The agenda of the meeting in April can be seen in French here.

Subscribe to our biweekly newsletter not to miss important reimbursement information.